- Tytuł:
- Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
- Autorzy:
- Źródło:
- In The Lancet 9-15 December 2023 402(10418):2197-2208
Czasopismo naukowe